Oscoz-Irurozqui Maitane, Villani Leonardo, Martinelli Silvia, Ricciardi Walter, Gualano Maria Rosaria
Red de Salud Mental de Gipuzkoa, Osakidetza-Basque Health Service, Gipuzkoa, Spain.
Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, Rome, 00168, Italy.
Sci Rep. 2025 Apr 9;15(1):12124. doi: 10.1038/s41598-025-96037-z.
Depression is an important public health issue. Over the years, the consumption of antidepressants has increased in the population, which on one hand may mean increased diagnostic accuracy, but on the other could mean a problem of inappropriate consumption and prescribing. The aim of the study is to analyze trends in antidepressant consumption and major drug classes in Italy in the last 15 years to provide useful public health insights for policymakers. Data were collected from Osservasalute and OsMed reports from 2008 to 2022. We included the overall consumption of antidepressants and the three subclasses of the most widely used antidepressant drugs: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). Data were expressed as the daily defined dose (DDD) per 1,000 inhabitants. A joinpoint analysis was conducted for each data point in order to describe the trend and identify the Annual Percentage Change (APC) and the Average Annual Percent Change (AAPC). In Italy, there was an increase in antidepressant consumption of 36.7% over the period. Overall, Joinpoint analysis shows a significant AAPC of + 2.31%. Analyzing the subclasses also showed a significant increase in the consumption of SSRIs (AAPC = 1.46%) and SNRIs (AAPC = + 2.14%). In contrast, there was a significant decrease in the consumption of TCAs (AAPC = - 1.46%). The trend of antidepressant use has been increasing steadily over the considered period. Public Health plays a key role in proposing solutions to improve the mental health of the population. Targeted interventions must be carried out to raise awareness among policy makers, clinicians and the population.
抑郁症是一个重要的公共卫生问题。多年来,抗抑郁药在人群中的消费量有所增加,这一方面可能意味着诊断准确性提高,但另一方面也可能意味着存在用药不当和处方不合理的问题。本研究的目的是分析意大利过去15年中抗抑郁药消费及主要药物类别的趋势,为政策制定者提供有用的公共卫生见解。数据收集自2008年至2022年的Osservasalute和OsMed报告。我们纳入了抗抑郁药的总体消费量以及使用最广泛的三类抗抑郁药物:选择性5-羟色胺再摄取抑制剂(SSRI)、5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI)以及三环类抗抑郁药(TCA)。数据以每1000名居民的每日限定剂量(DDD)表示。对每个数据点进行连接点分析,以描述趋势并确定年度百分比变化(APC)和平均年度百分比变化(AAPC)。在意大利,这一时期抗抑郁药消费量增长了36.7%。总体而言,连接点分析显示AAPC显著为+2.31%。对各亚类的分析还显示,SSRI的消费量显著增加(AAPC = 1.46%),SNRI的消费量也显著增加(AAPC = +2.14%)。相比之下,TCA的消费量显著下降(AAPC = -1.46%)。在所考虑的时期内,抗抑郁药的使用趋势一直在稳步上升。公共卫生在提出改善人群心理健康的解决方案方面发挥着关键作用。必须开展有针对性的干预措施,以提高政策制定者、临床医生和公众的认识。